Aragon Pharmaceuticals has raised $50 million in equity financing.
Aragon Pharma is developing small-molecule drugs to treat hormone-driven cancers.
Aragon says that existing hormone-blocking drugs don’t fully stop the hormones from stimulating growth of malignant prostate cells. ARN-509 adds a new blocking mechanism to more effectively shut down the hormones’ effects.
The company did not return calls for comment in time for this article.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity